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Embryonic stem cells derived from 
the inner cell mass of blastocyst stage 
embryos (ES cells) are capable of dif-
ferentiating into any cell type, offer-
ing the possibility of their use in cell 
transplantation therapies. However, the 
risk of rejection by the immune system 
and the bioethical issues inherent to the 
use of embryonic cells prompted the 
search for a mechanism of obtaining 
pluripotent cells from adult cells and 
thus, potentially self tissues. In 2006, 
Takahashi and Yamanaka succeeded in 
reprogramming adult fibroblasts to in-
duced pluripotent stem cells (iPSCs) by 
the forced expression of four transcrip-
tion factors, namely Sox2, Klf4, Oct4, 
and Myc, now called the “Yamanaka 
Factors” or SKOM [1]. Despite the 
subsequent successful generation of 
iPSCs derived from various sources, 
the understanding of the mechanism 
by which these four factors act has 
remained unclear, as well as the steps 
that progressively suppress the somatic 
cell program and activate ES cell marker 
genes. Two recent papers published in 
Cell Stem Cell shed light on these issues 
by dissecting both the individual role of 
the SKOM factors [2] and the sequential 
order of the full reprogramming process 
into initiation, maturation and stabiliza-
tion phases [3]. 
The two studies show that the con-
version of fibroblasts into an intermedi-
ate epithelial cell is crucial during the 
initial stages of reprogramming into 
iPSCs [2, 3]. This phenotypic change 
occurs through the induction of a mes-
enchymal to epithelial transition (MET) 
and is compatible with the fact that the 
morphology of the ES cells is more 
epithelial-like than mesenchymal-like 
and that mammary epithelial cells can 
be reprogrammed faster and with higher 
efficiency than fibroblasts [2]. The MET 
and the reverse process, epithelial to 
mesenchymal transition (EMT) are at 
the centre stage of epithelial plasticity 
and play a central role during embryo 
development. Moreover, the EMT is 
crucial during the progression of organ 
fibrosis and cancer [4]. 
In the first study, Li et al. [2] analyzed 
the effect of each reprogramming factor 
on the expression of EMT-MET induc-
ing genes. They showed that Sox2/Oct4 
suppresses the transcription of the EMT 
mediator Snail1, c-Myc downregulates 
the TGFβ signaling pathway and Klf4 
induces the expression of E-cadherin 
among other epithelial markers and 
decreases Snail1 protein levels (Figure 
1). In agreement with these findings, 
TGFβ1 treatment or Snail1 overex-
pression, both of which inhibit MET, 
reduces the formation of iPSCs [2], also 
consistent with recent results showing 
that TGFβ1 inhibitors promote nuclear 
reprogramming [5, 6]. The combined 
action of SKOM factors in the recipient 
fibroblasts is directed towards the re-
pression of the EMT program. As such, 
Snail1 transcription factor is a potent 
EMT inducer, E-Cadherin repressor and 
TGFβ1 is the main signaling pathway 
for the triggering of the EMT and the 
major activator of Snail1 transcription 
in physiological and pathological condi-
tions [4]. Thus, while Sox2/Oct4 repress 
EMT inducers, Myc prevents them from 
being reactivated by inhibiting TGFβ, 
and Klf4 reinforces the epithelial pro-
gram by directly inducing E-cadherin 
expression, altogether leading to the 
epithelialization of fibroblast or MET. 
Based on gene expression profiles 
during fibroblasts reprogramming, 
Samavarchi-Tehrani et al. [3] also con-
cluded that the MET is one of the initial 
changes that fibroblasts undergo dur-
ing cellular reprogramming and found 
that MET concurs with the inhibition 
of TGFβ and the activation of BMP7. 
BMP7 induces epithelialization and 
MET by reverting the TGFβ-induced 
EMT in a mouse model of renal fibro-
sis [7]. This indicates that TGFβ and 
BMP7 can act as antagonistic agents 
in epithelial plasticity, supporting that 
the SKOM factors together with BMP7 
favor the progression towards the epi-
thelial phenotype and reprogramming, 
and that BMP-7 administration during 
reprogramming significantly increases 
the number of iPSCs [3] (Figure 1). 
Interestingly, BMP7 activates the ex-
pression of the miR200 family, which 
in turn, are strong repressors of the EMT 
inducers and can also repress TGFβ (see 
[8] for a review). 
The initiation phase of reprogram-
ming to iPSCs is not accompanied by 
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the expression of ES cells markers [3]. 
In addition, the expression of genes as-
sociated with MET induction is reverted 
and cells return to the parental fibroblas-
tic profile after SKOM removal, indicat-
ing that the initiation phase is unstable 
and reversible [3]. The maturation 
phase leads to irreversible commitment 
to reprogramming and it is associated 
with the expression of ES cell markers 
including Nanog, which is recently de-
scribed as a mediator of embryonic and 
induced pluripotency [9]. Therefore, 
irreversibility and pluripotency seem to 
be linked and dependent on the acqui-
sition of Nanog expression during the 
maturation phase of the reprogramming 
process (Figure 1). 
Stem cell properties have been as-
sociated not only with ES cells or iPSCs 
but also with immortalized mammary 
epithelial cells that have undergone 
EMT, the reverse of the MET process 
[10, 11]. This seems to be at odd with the 
finding that MET is a crucial initial step 
towards pluripotency. The combination 
of EMT and stemness is particularly 
relevant during cancer progression, as 
cells delaminate from the primary tumor 
through a process of EMT that allows 
cell migration and dissemination to 
form metastasis. This is reminiscent of 
the EMT process that the embryo uses 
for similar purposes, the formation of 
different tissues and organs which cells 
originate far from their final destina-
tion [4]. The migratory cancer cell thus 
combines the mesenchymal phenotype 
necessary for efficient dissemination 
together with stem cell properties, as 
CSCs are defined by their ability to 
seed new tumors, to self-renew and to 
produce non-stem differentiated cells 
[12]. Interestingly, CSCs have not been 
shown to be pluripotent, making them 
different from iPSCs. Indeed, CSCs do 
not need pluripotency, as during me-
tastasis formation, cancer cells do not 
Figure 1 Schematic representation of the regulatory network for the generation of iPSCs and CSCs. During the initiation 
phase of fibroblast reprogramming the SKOM factors in combination with BMP7 and miR200 family members induce a mes-
enchymal to epithelial transition (MET) mainly through the repression of the EMT program. As such, Sox2/Oct4 repress the 
inducers of the epithelial to mesenchymal transition (EMT), c-Myc downregulates TGFβ signaling and Klf4 induces E-cadherin 
expression and decreases Snail1 protein levels (dotted line). After the MET, these intermediate epithelial cells do not express 
stem cell markers and maintain the ability to revert to the mesenchymal phenotype. The irreversible maturation/stabilization 
phase is marked by the onset of Nanog expression, key for the generation of pluripotency and iPSCs. During tumor progres-
sion, epithelial carcinoma cells or CSCs undergo EMT to acquire the ability to disseminate while maintaining some stem cell 
properties, but not pluripotency. These migrating CSCs generate distant metastasis upon suffering a MET and reverting to the 
differentiated state of the primary tumor (see text for details). BMP7, bone morphogentic protein; CSCs, cancer stem cells; 
iPSCs, induced pluripotent stem cells; TGFβ, transforming growth factor β.
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generate any cell type but revert to the 
phenotypes of the primary carcinoma 
[13]. If Nanog expression defines the 
irreversible commitment to full repro-
gramming and pluripotency, the predic-
tion would be that the migrating CSCs 
[14] should be Nanog negative or low, 
and their progeny in the metastasis is the 
result of a MET that produces epithelial 
cells resembling the primary tumor. Of 
note, this MET has some similarities 
with the reversible initiation phase 
during iPSCs reprogramming. The 
lack of Nanog could also allow these 
metastastic cells to maintain plasticity 
so that they could subsequently undergo 
another round of EMT that would al-
low the formation of new CSCs, in line 
with the proposed bidirectional inter-
convertibility between CSCs and non 
CSCs [12]. In summary, pluripotency 
and stemness are not equivalent terms, 
which may explain the paradox in the 
dynamics of the EMT/MET processes 
occurring during reprogramming and 
cancer progression. 
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